Kirr Marbach & Co. LLC IN Purchases Shares of 237,895 Royalty Pharma PLC $RPRX

Kirr Marbach & Co. LLC IN purchased a new stake in Royalty Pharma PLC (NASDAQ:RPRX) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 237,895 shares of the biopharmaceutical company’s stock, valued at approximately $11,412,000. Royalty Pharma makes up approximately 2.1% of Kirr Marbach & Co. LLC IN’s investment portfolio, making the stock its 19th largest holding.

Other institutional investors and hedge funds also recently modified their holdings of the company. Morgan Stanley grew its holdings in shares of Royalty Pharma by 25.2% during the fourth quarter. Morgan Stanley now owns 55,274,069 shares of the biopharmaceutical company’s stock worth $2,135,790,000 after buying an additional 11,110,115 shares in the last quarter. Capital International Investors boosted its position in Royalty Pharma by 14.3% during the 4th quarter. Capital International Investors now owns 31,104,309 shares of the biopharmaceutical company’s stock worth $1,201,870,000 after acquiring an additional 3,891,615 shares during the last quarter. State Street Corp boosted its position in Royalty Pharma by 3.7% during the 4th quarter. State Street Corp now owns 10,649,641 shares of the biopharmaceutical company’s stock worth $411,502,000 after acquiring an additional 376,888 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Royalty Pharma by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 7,719,843 shares of the biopharmaceutical company’s stock worth $297,465,000 after acquiring an additional 102,430 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in shares of Royalty Pharma by 9.7% in the fourth quarter. Victory Capital Management Inc. now owns 5,106,905 shares of the biopharmaceutical company’s stock valued at $197,331,000 after purchasing an additional 449,498 shares during the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Royalty Pharma news, EVP Marshall Urist sold 13,684 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $53.06, for a total value of $726,073.04. Following the sale, the executive vice president owned 31,881 shares in the company, valued at $1,691,605.86. This represents a 30.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 64,399 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $53.98, for a total value of $3,476,258.02. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 164,394 shares of company stock worth $8,498,892. Company insiders own 18.84% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on RPRX. JPMorgan Chase & Co. increased their target price on shares of Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Citigroup increased their price objective on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. TD Cowen reaffirmed a “buy” rating on shares of Royalty Pharma in a research report on Friday, February 27th. Finally, UBS Group upped their target price on Royalty Pharma from $51.00 to $57.00 and gave the stock a “buy” rating in a report on Tuesday, April 21st. Seven research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $53.71.

Royalty Pharma Price Performance

Shares of RPRX opened at $55.35 on Wednesday. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. The company’s fifty day simple moving average is $52.42 and its 200 day simple moving average is $46.31. Royalty Pharma PLC has a 1-year low of $34.08 and a 1-year high of $56.50. The company has a market cap of $31.87 billion, a price-to-earnings ratio of 37.65, a PEG ratio of 1.47 and a beta of 0.43.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The firm had revenue of $630.58 million during the quarter, compared to analysts’ expectations of $881.69 million. On average, research analysts forecast that Royalty Pharma PLC will post 5.05 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were paid a $0.235 dividend. This represents a $0.94 annualized dividend and a yield of 1.7%. The ex-dividend date was Friday, May 15th. Royalty Pharma’s dividend payout ratio (DPR) is 63.95%.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.